Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 Orphazyme to host Interim Report First Half 2021 investor call on August 31, 2021
2 Orphazyme reports business highlights and financial results
3 Orphazyme A/S (ORPH) CEO Christophe Bourdon On Q2 2021 Results
4 Orphazyme A/S (ORPH) Down 1.20% in Premarket Trading
5 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Orphazyme A/S of Class Action Lawsuit and Upcoming Deadline
6 Orphazyme A/S (ORPH) Up 0.98% in Premarket Trading
7 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orphazyme, CorMedix, Koninklijke Philips, and Sesen Bio and Encourages Investors to Contact the Firm
8 Orphazyme A/S (ORPH) has gained 0.77% Wednesday In Premarket Trading
9 CytRx Highlights Orphazyme's Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
10 Orphazyme A/S (ORPH) falls 1.92% in Light Trading on September 16
11 Premarket Mover: Orphazyme A/S (ORPH) Down 0.87%
12 ORPH FINAL DEADLINE ALERT: ROSEN, NATIONALLY REGARDED
13 Capital increase of 3,854 shares in Orphazyme A/S as a
14 SHAREHOLDER ALERT: Robbins LLP Announces that Orphazyme A/S (ORPH) is Being Sued for Misleading Shareholders
15 Orphazyme addresses recent trading activity
16 Capital increase of 170,131 shares in Orphazyme A/S as a
17 ORPH DEADLINE ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Orphazyme A/S Investors with LOSSES OVER $100K to Secure Counsel Before Important Deadline in Class Action
18 Articles of Association for Orphazyme A/S
19 Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC
20 DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
21 Orphazyme Cuts Outlook After Failing FDA Test in Latest Meme Stock News
22 Major shareholder announcement
23 Orphazyme establishes US headquarters in Chicago as the
24 Orphazyme ADS Share Price Soars in US Trading Hours as Meme Stocks Rise
25 The Law Offices of Frank R. Cruz Announces Investigation of Orphazyme A/S (ORPH) on Behalf of Investors
26 Final Deadline for Investors with Losses Exceeding $500K to Actively Participate in the Orphazyme A/S (ORPH) Class Action
27 Is Orphazyme a Winner in the Biotech Industry?
28 Orphazyme announces publication of results from its Phase 2/3 trial of arimoclomol in Niemann-Pick
29 Orphazyme Share Price, News: Brokerage Warns Over Latest Reddit Meme Stock
30 Bragar Eagel & Squire, PC Reminds Investors That Class
31 EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important Deadline – ORPH
32 Do Hedge Funds Love Orphazyme A/S (ORPH)?
33 SHAREHOLDER ALERT: Robbins LLP Reminds Investors that Orphazyme A/S (NASDAQ:ORPH) is Being Sued for Misleading Shareholders
34 Orphazyme A/S Investors: Last Days to Participate Actively
35 After Meme-Stock Rally, Key Orphazyme Shareholder Cuts Stake
36 Orphazyme A/S Skyrockets 984% to $56.70, CytRx Also Surges
37 Orphazyme announces topline results from pivotal trial of
38 New publication date for Orphazyme's Interim Report H1 2021
39 Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
40 ROSEN, A LEADING LAW FIRM, Encourages Orphazyme A/S
41 Pomerantz Law Firm Announces the Filing of a Class Action Against Orphazyme A/S and Certain Officers and Directors
42 EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Orphazyme A/S Investors With Losses to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH
43 Goldman Sachs Briefly Builds Stake in Meme Stock Orphazyme (ORPH)
44 Kim Stratton, CEO, resigns from Orphazyme
45 Orphazyme provides regulatory update on arimoclomol for NPC
46 Orphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in
47 Orphazyme submits European Marketing Authorisation Application for arimoclomol for treatment of Niemann-Pick disease Type C
48 Orphazyme stock losing half its value premarket, after rocketing fourfold the day before
49 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orphazyme A/S
50 IPO Launch: Orphazyme A/S Finalizes Terms For $100 Million U.S. IPO
51 CytRx Notes Orphazyme's Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis
52 Here's Why Orphazyme Shares Rocketed Higher on Wednesday
53 Rosen, A Leading Law Firm, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important September 7 Deadline in Securities Class Action
54 ORPHAZYME A/S CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Orphazyme A/S in the United States District Court for the Northern District of Illinois
55 Orphazyme accelerates arimoclomol pre-launch activities and
56 ORPH Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Orphazyme A/S Shareholders of Class Action and Encourages Shareholders to Contact the Firm
57 ORPH LOSS NOTICE: ROSEN A LEADING INVESTOR RIGHTS LAW FIRM Encourages Orphazyme A/S Investors With Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action
58 ORPH INVESTOR ALERT: Bernstein Liebhard LLP Announces that
59 ORPHAZYME INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Orpahzyme A/S Class Action Lawsuit
60 Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)
61 Is Orphazyme (ORPH) A Good Stock To Buy Now?
62 Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Orphazyme A/S (ORPH) on Behalf of Investors
63 Forbion Appoints Nanna Lüneborg as a General Partner
64 FDA Action Alert: Blueprint, Orphazyme and Eton
65 After Orphazyme's pipeline in a product bursts, the inevitable tide turns on its staffers
66 Orphazyme files final prospectus in connection with a global offering, consisting of initial public offering of
67 ORPH NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action
68 ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action
69 Orphazyme, Windeln Share Price Soar as Reddit Traders Pump Meme Stocks
70 CytRx Highlights Orphazyme's Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C
71 Busic v. Orphazyme A/S et al. – Global Legal Chronicle
72 ROSEN, A LONGSTANDING AND TRUSTED LAW FIRM, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline
73 Rosen, Trusted National Trial Counsel, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action
74 Orphazyme to showcase data on arimoclomol in Niemann-Pick
75 Orphazyme: Game Over, Man
76 Why Did Orphazyme (ORPH) Shares Skyrocket As Much As 1387% Today?
77 Orphazyme A/S May Look Like a Long Shot, but Things Aren't That Dire
78 Do Options Traders Know Something About Orphazyme (ORPH) Stock We Don't?
79 Orphazyme announces US FDA acceptance and Priority Review
80 Orphazyme phase 2 study of arimoclomol in Gaucher disease
81 Orphazyme A/S (ORPH) falls 4.93% to Close at $5.01 on August 17
82 Orphazyme A/S (ORPH) falls 2.40% to Close at $4.89 on August 18
83 CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C
84 Rosen, Top Ranked Investor Counsel, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action
85 ORPH Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Orphazyme A/S Shareholders of Class Action and Encourages Shareholders to Contact the Firm
86 ORPH, YMM & BZ Class Action Reminders and Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC
87 Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)
88 Orphazyme completes offering of 7,032,937 shares in a
89 Orphazyme's arimoclomol misses endpoints in a phase II/III
90 Orphazyme (ORPH) Stock Is Gaining Historical Momentum By 24.58% Today: Will It Continue To Surge? – Own Snap
91 Orphazyme A/S (ORPH) falls 9.24% on Moderate Volume August 12
92 CytRx Comments on Quarterly Results and Year-to-Date Progress
93 Orphazyme's arimoclomol receives US Fast Track Designation
94 ORPH Stock Forecast, Price & News (Orphazyme A/S)
95 ORPH BREAKING ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ORPH
96 CytRx Comments on Quarterly Results and Recent Strategic Initiatives
97 Orphazyme's Rare Lipid Disorder Drug Gets Priority Review from the FDA
98 Orphazyme: Recent Weakness Presents A Buying Opportunity
99 Orphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick
100 A Danish biotech stock surged 1387% during US trading hours for no apparent reason amid chatter that it's getting the meme-stock treatment